Editorial
doi: 10.1161/JAHA.118.011903.
Lipoprotein(a) Removal Still a Mystery
Affiliations
- PMID: 30755058
- PMCID: PMC6405664
- DOI: 10.1161/JAHA.118.011903
Item in Clipboard
Editorial
Lipoprotein(a) Removal Still a Mystery
J Am Heart Assoc.
.
Abstract
See Article by Shapiro et al.
Keywords: Editorials; LDL receptor; antisense silencing of LPA gene; cardiovascular risk; lipoprotein(a); proprotein convertase stabilisin/kexin type 9 inhibitor.
Comment on
-
Relationship Between Low-Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab.J Am Heart Assoc. 2019 Feb 19;8(4):e010932. doi: 10.1161/JAHA.118.010932. J Am Heart Assoc. 2019. PMID: 30755061 Free PMC article. Clinical Trial.
Similar articles
-
From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.Eur J Prev Cardiol. 2018 Nov;25(17):1843-1851. doi: 10.1177/2047487318792626. Epub 2018 Jul 30. Eur J Prev Cardiol. 2018. PMID: 30058841
-
Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.J Clin Lipidol. 2017 May-Jun;11(3):667-673. doi: 10.1016/j.jacl.2017.03.001. Epub 2017 Mar 9. J Clin Lipidol. 2017. PMID: 28506388 Clinical Trial.
-
Lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 inhibitors.Clin Res Cardiol Suppl. 2019 Apr;14(Suppl 1):45-50. doi: 10.1007/s11789-019-00099-z. Clin Res Cardiol Suppl. 2019. PMID: 30838555
-
Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Circulation. 2015 Oct 27;132(17):1648-66. doi: 10.1161/CIRCULATIONAHA.115.016080. Circulation. 2015. PMID: 26503748 Review.
-
Clinical guidance on the contemporary use of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies.Diabetes Obes Metab. 2019 Apr;21 Suppl 1:52-62. doi: 10.1111/dom.13637. Diabetes Obes Metab. 2019. PMID: 31002454 Review.
Cited by
-
Comprehensive Investigation of Circulating Biomarkers and Their Causal Role in Atherosclerosis-Related Risk Factors and Clinical Events.Circ Genom Precis Med. 2020 Dec;13(6):e002996. doi: 10.1161/CIRCGEN.120.002996. Epub 2020 Oct 30. Circ Genom Precis Med. 2020. PMID: 33125266 Free PMC article.
-
Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?J Clin Med. 2019 Nov 27;8(12):2073. doi: 10.3390/jcm8122073. J Clin Med. 2019. PMID: 31783529 Free PMC article. Review.
-
Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature.Biomolecules. 2025 Jan 22;15(2):162. doi: 10.3390/biom15020162. Biomolecules. 2025. PMID: 40001465 Free PMC article. Review.
References
-
- Kamstrup PR, Benn M, Tybjaerg‐Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population. Circulation. 2008;117:176–184. - PubMed
-
- Nestel PJ, Barnes EH, Tonkin AM, Simes J, Fournier M, White HD, Colquhoun DM, Blankenberg S, Sullivan DR. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33:2902–2908. - PubMed
-
- Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Lesogor S, Tsimikas S. Baseline and on‐statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient‐data meta‐analysis of statin outcome trials. Lancet. 2018;392:1311–1320. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
